{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:31:26Z","timestamp":1788211886774,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03261-0","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T08:52:12Z","timestamp":1750323132000},"page":"4013-4022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Obesity and Schizophrenia: Results of a Feasibility Study with Semaglutide to Assist Weight Loss"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-4050","authenticated-orcid":false,"given":"Adrian H.","family":"Heald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onagh","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Longson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Firth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Stedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akheel","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"de Hert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"3261_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0004867415625817","volume":"51","author":"AH Heald","year":"2017","unstructured":"Heald AH, Martin JL, Payton T, Khalid L, Anderson SG, Narayanan RP, De Hert M, Yung A, Livingston M. Changes in metabolic parameters in patients with severe mental illness over a 10-year period: a retrospective cohort study. Aust N Z J Psychiatry. 2017;51:75\u201382.","journal-title":"Aust N Z J Psychiatry"},{"key":"3261_CR2","doi-asserted-by":"crossref","unstructured":"Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16:1205\u201318.","DOI":"10.1017\/S1461145712001277"},{"key":"3261_CR3","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686\u201396.","journal-title":"Am J Psychiatry"},{"key":"3261_CR4","doi-asserted-by":"crossref","unstructured":"Cooper SJ, Reynolds GP; With expert co-authors (in alphabetical order): Barnes T, England E, Haddad PM, Heald A, Holt R, Lingford-Hughes A, Osborn D, McGowan O, Patel MX, Paton C, Reid P, Shiers D, Smith J. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30:717\u201348.","DOI":"10.1177\/0269881116645254"},{"key":"3261_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jamapsychiatry.2014.1314","volume":"71","author":"CU Correll","year":"2014","unstructured":"Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiat. 2014;71:1350\u201363.","journal-title":"JAMA Psychiat"},{"key":"3261_CR6","doi-asserted-by":"crossref","unstructured":"Harrison RNS, Gaughran F, Murray RM, Lee SH, Cano JP, Dempster D, Curtis CJ, Dima D, Patel H, de Jong S, Breen G. Development of multivariable models to predict change in Body Mass Index within a clinical trial population of psychotic individuals. Sci Rep. 2017;7:14738.","DOI":"10.1038\/s41598-017-15137-7"},{"key":"3261_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12991-023-00485-8","volume":"23","author":"A Heald","year":"2024","unstructured":"Heald A, Daly C, Warner-Levy JJ, Williams R, Meehan C, Livingston M, Pillinger T, Hussain L, Firth J. Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester. UK Ann Gen Psychiatry. 2024;23:1.","journal-title":"UK Ann Gen Psychiatry"},{"key":"3261_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/070674371405900203","volume":"59","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ, Kennedy JL, M\u00fcller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry. 2014;59:76\u20138.","journal-title":"Can J Psychiatry"},{"key":"3261_CR9","first-page":"25","volume":"9","author":"AJ Perkins","year":"2023","unstructured":"Perkins AJ, Khandker R, Overley A, Solid CA, Chekani F, Roberts A, Dexter P, Boustani MA, Hulvershorn L. Association of antipsychotic-related weight gain with treatment adherence and switching using electronic medical records data. Prim Care Compan CNS Disord. 2023;9:25.","journal-title":"Prim Care Compan CNS Disord"},{"key":"3261_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.genhosppsych.2008.09.012","volume":"31","author":"LA Chwastiak","year":"2009","unstructured":"Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, Lieberman JA. The impact of obesity on health care costs among persons with schizophrenia. Gen Hosp Psychiatry. 2009;31:1\u20137.","journal-title":"Gen Hosp Psychiatry"},{"key":"3261_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","volume":"22","author":"RM Sandsdal","year":"2023","unstructured":"Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen JB, Antoniades C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22:41.","journal-title":"Cardiovasc Diabetol"},{"key":"3261_CR12","doi-asserted-by":"crossref","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002.","DOI":"10.1056\/NEJMoa2032183"},{"key":"3261_CR13","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316.","DOI":"10.1056\/NEJMoa2206038"},{"key":"3261_CR14","unstructured":"https:\/\/icd.who.int\/browse10\/2019\/en. Accessed 24 Jan 2025."},{"key":"3261_CR15","unstructured":"https:\/\/www.legislation.gov.uk\/ukpga\/1983\/20\/contents. Accessed 31 Dec 2024."},{"key":"3261_CR16","unstructured":"https:\/\/www.nice.org.uk\/guidance\/ta875. Accessed 24 Jan 2025."},{"key":"3261_CR17","unstructured":"https:\/\/euroqol.org\/information-and-support\/euroqol-instruments\/eq-5d-5l. Accessed 1 Feb 2025."},{"key":"3261_CR18","first-page":"2203310","volume":"25","author":"AJ Perkins","year":"2023","unstructured":"Perkins AJ, Khandker R, Overley A, et al. Association of antipsychotic- related weight gain with treatment adherence and switching using electronic medical records data. Prim Care Compan CNS Disord. 2023;25:2203310.","journal-title":"Prim Care Compan CNS Disord"},{"issue":"18","key":"3261_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","volume":"1","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic drug-related weight gain and its treatment. Am J Psychiatry. 2024;1(18):26\u201338.","journal-title":"Am J Psychiatry"},{"key":"3261_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/oby.2007.133","volume":"16","author":"RL Kolotkin","year":"2008","unstructured":"Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuomari AV, L\u2019italien GJ, Mitchell JE. Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder. Obesity (Silver Spring). 2008;16:749\u201354.","journal-title":"Obesity (Silver Spring)"},{"key":"3261_CR21","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","volume":"6","author":"J Firth","year":"2019","unstructured":"Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019;6:675\u2013712.","journal-title":"Lancet Psychiatry"},{"key":"3261_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.573479","volume":"11","author":"V Mazereel","year":"2020","unstructured":"Mazereel V, Detraux J, Vancampfort D, et al. Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness. Front Endocrinol (Lausanne). 2020;11: 573479.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3261_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16:163\u201380.","journal-title":"World Psychiatry"},{"key":"3261_CR24","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.3390\/nu11112611","volume":"11","author":"M Uusitupa","year":"2019","unstructured":"Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, Hermansen K, Pfeiffer A, Thanopoulou A, Salas-Salvad\u00f3 J, Schwab U, Sievenpiper JL. Prevention of type 2 diabetes by lifestyle changes: a systematic review and meta-analysis. Nutrients. 2019;11:2611.","journal-title":"Nutrients"},{"key":"3261_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-021-01413-4","volume":"20","author":"C Sinning","year":"2021","unstructured":"Sinning C, Makarova N, V\u00f6lzke H, Schnabel RB, Ojeda F, D\u00f6rr M, Felix SB, Koenig W, Peters A, Rathmann W, Sch\u00f6ttker B, Brenner H, Veronesi G, Cesana G, Brambilla P, Palosaari T, Kuulasmaa K, Nj\u00f8lstad I, Mathiesen EB, Wilsgaard T, Blankenberg S, S\u00f6derberg S, Ferrario MM, Thorand B. Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium. Cardiovasc Diabetol. 2021;20:223.","journal-title":"Cardiovasc Diabetol"},{"key":"3261_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.genhosppsych.2023","volume":"85","author":"KM Miley","year":"2023","unstructured":"Miley KM, Hooker SA, Crain AL, O\u2019Connor PJ, Haapala JL, Bond DJ, Rossom RC. 30-year cardiovascular disease risk for young adults with serious mental illness. Gen Hosp Psychiatry. 2023;85:139\u201347. https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.","journal-title":"Gen Hosp Psychiatry"},{"key":"3261_CR27","unstructured":"https:\/\/www.legislation.gov.uk\/ukpga\/1983\/20\/contents. Accessed 1 Feb 2025."},{"key":"3261_CR28","doi-asserted-by":"publisher","first-page":"10147","DOI":"10.1016\/j.diabet.2023.101470","volume":"49","author":"M Monney","year":"2023","unstructured":"Monney M, Jornayvaz FR, Gariani K. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab. 2023;49:10147.","journal-title":"Diabetes Metab"},{"key":"3261_CR29","doi-asserted-by":"publisher","first-page":"14656230","DOI":"10.1016\/j.brainres.2019.146562","volume":"1727","author":"E Jerlhag","year":"2020","unstructured":"Jerlhag E. Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1. Brain Res. 2020;1727:14656230.","journal-title":"Brain Res"},{"key":"3261_CR30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170671","volume":"8","author":"V Chuong","year":"2023","unstructured":"Chuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8: e170671.","journal-title":"JCI Insight"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03261-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03261-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03261-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:30:35Z","timestamp":1757190635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03261-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3261"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03261-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Adrian H Heald, Gavin Reynolds, Isabel Nash, Onagh Boyle, Chris Daly, Damien Longson, Donal O\u2019Shea, Joseph Ingram, Richard Holt, Joseph Firth, Mike Stedman, Akheel Syed, Marc de Hert have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This intervention formed part of usual care based on clinical need. Therefore ethical approval was not sought. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. This was a service improvement project. The UK Health Research Authority decision tool did not consider this study to be research and therefore NHS Research Ethics Committee review was not required. All patients who received semaglutide gave verbal consent to receiving this medication as part of their usual care. Their consent was recorded in the electronic patient hospital record.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}